Decision Resources, Inc. Release: The Majority of Surveyed U.S. Oncologists Identified FOLFIRINOX as the Most Efficacious Treatment for Advanced Pancreatic Cancer, When Compared to Other Currently Available Therapies
3/3/2011 10:26:02 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. oncologists (57 percent) identified FOLFIRINOX* as the most efficacious treatment for advanced pancreatic cancer, when compared to other currently available agents. Patients with advanced pancreatic cancer who received FOLFIRINOX experienced a considerably longer median overall survival compared with patients who received gemcitabine (Eli Lilly’s Gemzar, generics) monotherapy.
comments powered by